Latest News & Features
Europe
EWHC ruling discusses application of EPO case law regarding lack of plausibility and lack of technical contribution | Court had earlier overturned a first-instance decision allowing an injunction against Glenmark’s diabetes generic | AstraZeneca intends to appeal. 29 April 2025
Africa
Genomic innovations involve vast amounts of research, making patents, copyrights, and trade secrets vital, explains Olusola Tunmise-Ajani of Inventa International. 29 April 2025
Americas
Proposed patent legislation will save US innovation and counter the ‘existential threat’ that China poses to the West, hears Sarah Speight. 29 April 2025
Americas
US district judge reduces award payable to Insulet by EOFlow to $59.4m l Dispute concerns wearable insulin patch pumps l Injunction remains but with allowance for users to access device temporarily. 29 April 2025
Americas
Case looked at whether generic treatment infringes ‘fridge temperature limitation method’ | Ruling underscores importance of clear labelling in drug patent infringement suits. 24 April 2025
Europe
Following the Unified Patent Court’s recent Meril v Edwards decision, Agathe Michel-de Cazotte & Ben Chapman of Carpmaels & Ransford examine the court’s treatment of obviousness to date. 24 April 2025
Americas
As the US legal sector comes under political pressure for its inclusion efforts, LSIPR's sister magazine reveals its Top 100 for 2025, highlighting the individuals fighting to keep progress at the heart of IP. 24 April 2025
Americas
Generative AI is transforming the biotech industry, so it’s crucial to have an IP strategy—in particular, for trade secret and/or patent protection. Dean Pelletier of Pelletier Law explains. 24 April 2025
Europe
Gene editing company ToolGen “seeks fair licensing agreement” for alleged infringement by rival | High-value sickle cell treatment CASGEVY was “born from ToolGen’s proprietary CRISPR RNP tech” says complaint | Potter Clarkson instructed. 22 April 2025
Europe
For those willing to undertake the complexity, in vivo cell therapy could redefine the economics and logistics of cell-based treatment, says Adam Gregory of Mewburn Ellis. 22 April 2025